Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 5
Submit an article Journal homepage
2,969
Views
95
CrossRef citations to date
0
Altmetric
Brief Report

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

Stephan KrugerDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Marie-Louise LegensteinDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Verena RösgenDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Michael HaasDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Dominik Paul ModestDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany;DKTK, German Cancer Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Christoph Benedikt WestphalenDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Steffen OrmannsInstitute of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Thomas KirchnerDKTK, German Cancer Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany;Institute of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany
,
Volker HeinemannDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany;DKTK, German Cancer Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Stefan HoldenriederInstitute of Laboratory Medicine, German Heart Centre Munich, Technical University of Munich, Munich, Germany;Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany
&
Stefan BoeckDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany;DKTK, German Cancer Consortium, German Cancer Research Center (DKFZ), Heidelberg, GermanyCorrespondence[email protected]
 show all
Article: e1310358 | Received 23 Dec 2016, Accepted 17 Mar 2017, Published online: 08 May 2017

Citations (95)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Jinfan Sun, Shuenqin Hu & Xiuying Li. (2023) Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers. Biomarkers 28:6, pages 477-485.
Read now
Haisheng Hu, Chuanxu Cai, Mingshan Xue, Jiaying Luo, Chenxi Liao, Huimin Huang & Baoqing Sun. (2020) Increased MMP8 Levels in Atopic Chronic Obstructive Pulmonary Disease: A Study Testing Multiple Immune Factors in Atopic and Non-Atopic Patients. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1839-1848.
Read now
Benjamin Bian, Daniele Fanale, Nelson Dusetti, Julie Roque, Sonia Pastor, Anne-Sophie Chretien, Lorena Incorvaia, Antonio Russo, Daniel Olive & Juan Iovanna. (2019) Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. OncoImmunology 8:4.
Read now
Francesca R. Mariotti, Stefania Petrini, Tiziano Ingegnere, Nicola Tumino, Francesca Besi, Francesca Scordamaglia, Enrico Munari, Silvia Pesce, Emanuela Marcenaro, Alessandro Moretta, Paola Vacca & Lorenzo Moretta. (2019) PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. OncoImmunology 8:3.
Read now

Articles from other publishers (91)

Xu Wang, Lingyan Yan, Jihua Guo & Rong Jia. (2024) An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3. International Immunopharmacology 126, pages 111280.
Crossref
Lars Schröder, Alexander B. A. Rupp, Kathrin M. E. Gihr, Makbule Kobilay, Christian M. Domroese, Michael R. Mallmann & Stefan Holdenrieder. (2023) Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies. Cancers 15:20, pages 5081.
Crossref
David Digomann, Max Heiduk, Charlotte Reiche, Jessica Glück, Christoph Kahlert, Peter Mirtschink, Anna Klimova, Florian Bösch, Torsten Tonn, Jochen Gaedcke, Michael Ghadimi, Jürgen Weitz, Lena Seifert & Adrian M. Seifert. (2023) Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. npj Precision Oncology 7:1.
Crossref
Yang Ruan, Longlong Xie & Aijun Zou. (2023) Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children. Journal of Cancer Research and Clinical Oncology 149:12, pages 10841-10850.
Crossref
Dongxue Liu, Linlin Hu & Hua Shao. (2023) Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers. Cancer Chemotherapy and Pharmacology 92:3, pages 165-179.
Crossref
Yangyang Ding, Cheng Sun, Linhui Hu, Shudao Xiong & Zhimin Zhai. (2023) Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis. Annals of Hematology 102:9, pages 2425-2434.
Crossref
Francesca Romana Mariotti, Tiziano Ingegnere, Nadine Landolina, Paola Vacca, Enrico Munari & Lorenzo Moretta. (2023) Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells. Frontiers in Immunology 14.
Crossref
Hidetomo Himuro, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, Feifei Wei, Shun Horaguchi, Kayoko Tsuji, Yasunobu Mano, Haruhiro Saito, Koichi Azuma & Tetsuro Sasada. (2023) Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors. Cancer Immunology, Immunotherapy 72:8, pages 2829-2840.
Crossref
Thanos Tsaktanis, Mathias Linnerbauer, Lena Lößlein, Daniel Farrenkopf, Oliver Vandrey, Anne Peter, Ana Cirac, Tobias Beyer, Lucy Nirschl, Verena Grummel, Mark Mühlau, Matthias Bussas, Bernhard Hemmer, Francisco J Quintana & Veit Rothhammer. (2023) Regulation of the programmed cell death protein 1/programmed cell death ligand 1axis in relapsing-remitting multiple sclerosis. Brain Communications.
Crossref
Jian Ruan, Zhihong Zhao, Yuting Qian, Ruilian Xu, Guixiang Liao & Feng-Ming (Spring) Kong. (2023) The predictive role of soluble programmed death ligand 1 in digestive system cancers. Frontiers in Oncology 13.
Crossref
Yu Pan, Jianfeng Gao, Jiajing Lin, Yuan Ma, Zelin Hou, Yali Lin, Shi Wen, Minggui Pan, Fengchun Lu & Heguang Huang. (2023) High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. Frontiers in Endocrinology 14.
Crossref
Ivan Pourmir, Alain Gey, Joséphine Pineau, Céleste Lebbe & Eric Tartour. (2023) Biomarqueurs prédictifs de la réponse à l’immunothérapie dans les mélanomes. Bulletin de l'Académie Nationale de Médecine 207:6, pages 769-778.
Crossref
Klara Dorman, Miriam Gerckens, Stephan Kruger, Kimberly Krueger, Zsuzsanna Mayer, Alexander Rupp, Danmei Zhang, Lena Weiss, C. Benedikt Westphalen, Michael Haas, Michael Guenther, Steffen Ormanns, Frank Klawonn, Jens Werner, Michael von Bergwelt-Baildon, Volker Heinemann, Stefan Boeck & Stefan Holdenrieder. (2022) Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers. Journal of Cancer Research and Clinical Oncology 149:6, pages 2463-2474.
Crossref
Sai Pan, Wenting Zhao, Yizhan Li, Zhijun Ying, Yihong Luo, Qinchuan Wang, Xiawei Li, Wenjie Lu, Xin Dong, Yulian Wu & Xifeng Wu. (2023) Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins. Frontiers in Immunology 14.
Crossref
Se Jun Park, Ju Yeon Park, Kabsoo Shin, Tae Ho Hong, MyungAh Lee, Younghoon Kim & In-Ho Kim. (2023) Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer. BMC Cancer 23:1.
Crossref
Lingeng Lu, Evan Risch, Ruth Halaban, Pinyi Zhen, Antonella Bacchiocchi & Harvey A. Risch. (2023) Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. International Immunopharmacology 118, pages 110092.
Crossref
Ling Yi, Xiaojue Wang, Siyun Fu, Zhuohong Yan, Tianyu Ma, Siqi Li, Panjian Wei, Hongtao Zhang & Jinghui Wang. (2023) Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. Discover Oncology 14:1.
Crossref
Yinjun He, Xiang Zhang, Ming Zhu, Wenguang He, Hanju Hua, Feng Ye, Xile Zhou, Nan Chen, Yandong Li, Weixiang Zhong, Guosheng Wu, Hui Cai & Weiqin Jiang. (2023) Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. Journal of Translational Medicine 21:1.
Crossref
Francesca Torrini, Giada Goletta, Pasquale Palladino, Simona Scarano & Maria Minunni. (2023) A LysLysLys-tag as trigger in polynorepinephrine epitope imprinting: The case study of soluble PD-L1 detection in serum by optical-based sensing. Biosensors and Bioelectronics 220, pages 114806.
Crossref
Xin Chen, Jie Li, Yue Chen, Ziting Que, Jiawei Du & Jianqiong Zhang. (2022) B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy. International Journal of Molecular Sciences 23:23, pages 15005.
Crossref
Chang-cheng Zhao, Ling Chen, Xin-kai Hu, Jing-ru Tang, Yun Wang, Xiao-dan Zha, Jing Ge, Lun-shan Lu & Jing Yang. (2022) Plasma TIGIT Level Is a Possible Marker in HIV-Related Liver Damage. Doklady Biochemistry and Biophysics 506:1, pages 231-236.
Crossref
Corinna U. Keber, Marcus Derigs, Carolin Schultz, Moritz Wegner, Susanne Lingelbach, Viktoria Wischmann, Rainer Hofmann, Carsten Denkert, Axel Hegele & Jörg Hänze. (2022) Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood. Cancer Immunology, Immunotherapy 71:10, pages 2381-2389.
Crossref
Daniele Fanale, Lidia Rita Corsini, Chiara Brando, Sofia Cutaia, Mariano Catello Di Donna, Clarissa Filorizzo, Maria Chiara Lisanti, Ugo Randazzo, Luigi Magrin, Raffaella Romano, Tancredi Didier Bazan Russo, Daniel Olive, Salvatore Vieni, Gianni Pantuso, Vito Chiantera, Antonio Russo, Viviana Bazan & Juan Lucio Iovanna. (2022) Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?. Frontiers in Oncology 12.
Crossref
Shuping Li, Ling Yi, Xiqing Wei, Jinguo Zhang, Xiaojue Wang, Chang Jiang, Zhuohong Yan, Liwei Song, Bin Yang, Panjian Wei, Xiang Gao, Jinghui Wang, Hongtao Zhang & Jian Zhang. (2022) Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. Frontiers in Cardiovascular Medicine 9.
Crossref
Sheng Wei Pan, Wei Juin Su, Yu Jiun Chan, Mei Lin Ho, Jia Yih Feng, Chin Chung Shu, Jann Yuan Wang, Hao Chien Wang, Chong Jen Yu & Yuh Min Chen. (2022) Disease Progression in Patients With Nontuberculous Mycobacterial Lung Disease of Nodular Bronchiectatic (NB) Pattern: The Roles of Cavitary NB and Soluble Programmed Death Protein-1. Clinical Infectious Diseases 75:2, pages 239-247.
Crossref
Weifang Shao, Yanhua Xu, Suzhen Lin, Junli Gao, Junshun Gao & Hong Wang. (2022) The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer. Frontiers in Oncology 12.
Crossref
Xuejiao Li, Huan Du, Shenghua Zhan, Wenting Liu, Zhangyu Wang, Jing Lan, Longxiang PuYang, Yuqiu Wan, Qiuxia Qu, Sining Wang, Yang Yang, Qin Wang & Fang Xie. (2022) The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer. Frontiers in Immunology 13.
Crossref
Enrico Zelin, Carlo Alberto Maronese, Arianna Dri, Ludovica Toffoli, Nicola Di Meo, Gianluca Nazzaro & Iris Zalaudek. (2022) Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. Journal of Clinical Medicine 11:12, pages 3364.
Crossref
Mengke Niu, Yiming Liu, Ming Yi, Dechao Jiao & Kongming Wu. (2022) Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. Frontiers in Immunology 13.
Crossref
Yu Xing, Juntao Liu, Jinping Luo, Tao Ming, Gucheng Yang, Shuai Sun, Shengwei Xu, Xinrong Li, Enhui He, Fanli Kong, Shi Yan, Yue Yang & Xinxia Cai. (2022) A Dual-Channel Intelligent Point-of-Care Testing System for Soluble Programmed Death-1 and Programmed Death-Ligand 1 Detection Based on Folding Paper-Based Immunosensors. ACS Sensors 7:2, pages 584-592.
Crossref
Ning Tan, Hao Luo, Qian Kang, Jiali Pan, Ran Cheng, Hongli Xi, Hongyu Chen, Yifan Han, Yuqing Yang & Xiaoyuan Xu. (2022) High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Research 309, pages 198660.
Crossref
Koichiro Fujisue, Eiichiro Yamamoto, Daisuke Sueta, Masafumi Takae, Taiki Nishihara, Takashi Komorita, Hiroki Usuku, Kenshi Yamanaga, Miwa Ito, Tadashi Hoshiyama, Hisanori Kanazawa, Seiji Takashio, Yuichiro Arima, Satoshi Araki, Hirofumi Soejima, Koichi Kaikita, Kenichi Matsushita & Kenichi Tsujita. (2022) Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome. International Journal of Cardiology 349, pages 1-6.
Crossref
Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Katsiaryna Marhelava, Anna Burdzinska, Angelika Muchowicz, Agnieszka Goral, Andriy Zhylko, Karolina Soroczynska, Kuba Retecki, Marta Krawczyk, Marta Klopotowska, Zofia Pilch, Leszek Paczek, Karl-Johan Malmberg, Sébastien Wälchli, Magdalena Winiarska & Radoslaw Zagozdzon. (2022) PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. Journal for ImmunoTherapy of Cancer 10:1, pages e002500.
Crossref
Ryotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Rie Onoue, Kazuyuki Hamada, Yutaro Kubota, Atsushi Horiike, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Junji Tsurutani, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Shinichi Kobayashi, Takuya Tsunoda & Satoshi Wada. (2021) Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies. Biomedicines 9:12, pages 1929.
Crossref
Sai Mummareddy, Stuti Pradhan, Ashwin Narasimhan & Arutselvan Natarajan. (2021) On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy. Biosensors 11:12, pages 500.
Crossref
Xinfang Yu, Wei Li, Ken H. Young & Yong Li. (2021) Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave. Biomedicines 9:11, pages 1702.
Crossref
Andreia Gameiro, Catarina Nascimento, Jorge Correia & Fernando Ferreira. (2021) VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes. Cancers 13:21, pages 5559.
Crossref
Anna Reischer, Stephan Kruger & Michael von Bergwelt-Baildon. (2021) Checkpoint-Inhibitoren – aktuelle Versorgungsstandards und Zukunftstrends. DMW - Deutsche Medizinische Wochenschrift 146:17, pages 1108-1118.
Crossref
Honggang Ying, Xiaozhen Zhang, Yi Duan, Mengyi Lao, Jian Xu, Hanshen Yang, Tingbo Liang & Xueli Bai. (2021) Non-cytomembrane PD-L1: An atypical target for cancer. Pharmacological Research 170, pages 105741.
Crossref
Yu Xing, Juntao Liu, Shuai Sun, Tao Ming, Yang Wang, Jinping Luo, Guihua Xiao, Xinrong Li, Jingyu Xie & Xinxia Cai. (2021) New electrochemical method for programmed death-ligand 1 detection based on a paper-based microfluidic aptasensor. Bioelectrochemistry 140, pages 107789.
Crossref
Marzia Del Re, Caterina Vivaldi, Eleonora Rofi, Francesca Salani, Stefania Crucitta, Silvia Catanese, Lorenzo Fontanelli, Valentina Massa, Federico Cucchiara, Lorenzo Fornaro, Annalisa Capuano, Stefano Fogli, Enrico Vasile & Romano Danesi. (2021) Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Cancers 13:15, pages 3738.
Crossref
Christoph Roderburg, Sven H. Loosen, Jan Bednarsch, Patrick H. Alizai, Anjali A. Roeth, Sophia M. Schmitz, Mihael Vucur, Mark Luedde, Pia Paffenholz, Frank Tacke, Christian Trautwein, Tom F. Ulmer, Ulf Peter Neumann & Tom Luedde. (2021) Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma. International Journal of Molecular Sciences 22:12, pages 6569.
Crossref
Christian Bailly, Xavier Thuru & Bruno Quesnel. (2021) Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers 13:12, pages 3034.
Crossref
Nur Amira Khairil Anwar, Muhammad Najmi Mohd Nazri, Ahmad Hafiz Murtadha, Elis Rosliza Mohd Adzemi, Venugopal Balakrishnan, Khairul Mohd Fadzli Mustaffa, Tengku Ahmad Damitri Al-Astani Tengku Din, Maya Mazuwin Yahya, Juhara Haron & Noor Fatmawati Mokshtar. (2021) Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochimica et Biophysica Sinica 53:8, pages 961-978.
Crossref
Felix Ritzmann, Kai Borchardt, Giovanna Vella, Praneeth Chitirala, Adrian Angenendt, Christian Herr, Michael D. Menger, Markus Hoth, Annette Lis, Rainer M. Bohle, Robert Bals & Christoph Beisswenger. (2021) Blockade of PD-1 decreases neutrophilic inflammation and lung damage in experimental COPD. American Journal of Physiology-Lung Cellular and Molecular Physiology 320:5, pages L958-L968.
Crossref
Tudor Mocan, Maria Ilies, Iuliana Nenu, Rares Craciun, Adelina Horhat, Ruxandra Susa, Iulia Minciuna, Ioana Rusu, Lavinia-Patricia Mocan, Andrada Seicean, Cristina Adela Iuga, Nadim Al Hajjar, Mihaela Sparchez, Daniel-Corneliu Leucuta & Zeno Sparchez. (2021) Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. International Immunopharmacology 94, pages 107467.
Crossref
Daniele Fanale, Lorena Incorvaia, Giuseppe Badalamenti, Ida De Luca, Laura Algeri, Annalisa Bonasera, Lidia Rita Corsini, Chiara Brando, Antonio Russo, Juan Lucio Iovanna & Viviana Bazan. (2021) Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. Cancers 13:9, pages 2118.
Crossref
Gaopeng Li, Guoliang Wang, Fenqing Chi, Yuqi Jia, Xi Wang, Quankai Mu, Keru Qin, Xiaoxia Zhu, Jing Pang, Baixue Xu, Guangen Feng, Yuhu Niu, Tao Gong, Hongwei Zhang, Xiushan Dong, Ting Liu, Jinfeng Ma, Zefeng Gao, Kai Tao, Feng Li, Jun Xu & Baofeng Yu. (2021) Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer. Journal for ImmunoTherapy of Cancer 9:3, pages e002218.
Crossref
Gorka Larrinaga, Jon Danel Solano-Iturri, Peio Errarte, Miguel Unda, Ana Loizaga-Iriarte, Amparo Pérez-Fernández, Enrique Echevarría, Aintzane Asumendi, Claudia Manini, Javier C. Angulo & José I. López. (2021) Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. Cancers 13:4, pages 667.
Crossref
Roberta Carosio, Vincenzo Fontana, Luca Mastracci, Paola Ferro, Federica Grillo, Barbara Banelli, Pier Aldo Canessa, Paolo Dessanti, Antonella Vigani, Anna Morabito, Ulrich Pfeffer, Alessandro Poggi, Silvio Roncella & Maria Pia Pistillo. (2020) Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. Journal of Cancer Research and Clinical Oncology 147:2, pages 459-468.
Crossref
Heli Vajavaara, Julie Bondgaard Mortensen, Suvi-Katri Leivonen, Ida Monrad Hansen, Maja Ludvigsen, Harald Holte, Judit Jørgensen, Mette Bjerre, Francesco d’Amore & Sirpa Leppä. (2021) Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma. Cancers 13:3, pages 398.
Crossref
Sara Ravasio. 2021. Bio-Nanomedicine for Cancer Therapy. Bio-Nanomedicine for Cancer Therapy 327 347 .
Karolina Okła, Alicja Rajtak, Arkadiusz Czerwonka, Marcin Bobiński, Anna Wawruszak, Rafał Tarkowski, Wiesława Bednarek, Justyna Szumiło & Jan Kotarski. (2020) Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1. Journal of Translational Medicine 18:1.
Crossref
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, Yuxiang Fu & Guixiang Liao. (2020) Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. Frontiers in Immunology 11.
Crossref
Linda Quatrini, Francesca Romana Mariotti, Enrico Munari, Nicola Tumino, Paola Vacca & Lorenzo Moretta. (2020) The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers 12:11, pages 3285.
Crossref
Nikolaos Patsoukis, Qi Wang, Laura StraussVassiliki A. Boussiotis. (2020) Revisiting the PD-1 pathway. Science Advances 6:38.
Crossref
Alison Betts & Piet H. van der Graaf. (2020) Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology. Clinical Pharmacology & Therapeutics 108:3, pages 528-541.
Crossref
Guoliang Wang, Lejian He, Shengcai Wang, Meng Zhang, Yanzhen Li, Qiaoyin Liu, Nian Sun, Xuexi Zhang, Yuwei Liu, Jie Zhang, Jun Tai & Xin Ni. (2020) EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism 105:8, pages e2970-e2981.
Crossref
F.R. Mariotti, L. Quatrini, E. Munari, P. Vacca, N. Tumino, G. Pietra, M.C. Mingari & L. Moretta. (2020) Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. British Journal of Pharmacology 177:13, pages 2889-2903.
Crossref
Catarina Nascimento, Ana Catarina Urbano, Andreia Gameiro, João Ferreira, Jorge Correia & Fernando Ferreira. (2020) Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes. Cancers 12:6, pages 1386.
Crossref
Manuela Tiako Meyo, Anne Jouinot, Etienne Giroux-Leprieur, Elizabeth Fabre, Marie Wislez, Marco Alifano, Karen Leroy, Pascaline Boudou-Rouquette, Camille Tlemsani, Nihel Khoudour, Jennifer Arrondeau, Audrey Thomas-Schoemann, Hélène Blons, Audrey Mansuet-Lupo, Diane Damotte, Michel Vidal, François Goldwasser, Jérôme Alexandre & Benoit Blanchet. (2020) Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers 12:2, pages 473.
Crossref
Masaaki Ito, Satoshi Yajima, Takashi Suzuki, Yoko Oshima, Tatsuki Nanami, Makoto Sumazaki, Fumiaki Shiratori, Kimihiko Funahashi, Naobumi Tochigi & Hideaki Shimada. (2019) High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer. Cancer Medicine 9:4, pages 1321-1327.
Crossref
Shujun Liu, Yadi Zhu, Chenxi Zhang, Xiangrui Meng, Bo Sun, Guojun Zhang, Yubo Fan & Xixiong Kang. (2020) The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. Frontiers in Oncology 10.
Crossref
A. A. Korotaeva, N. V. Apanovich, E. A. Braga, V. B. Matveev & A. V. Karpukhin. (2020) Current advances in kidney cancer immunotherapy. Cancer Urology 15:4, pages 30-38.
Crossref
Sanna Iivanainen & Jussi P. Koivunen. (2020) Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. International Journal of Molecular Sciences 21:2, pages 556.
Crossref
Ye Hu, Rui Zhang & Gang Chen. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints 455 483 .
Stephan Kruger, Matthias Ilmer, Sebastian Kobold, Bruno L. Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard W. Renz, Jan G. D’Haese, Hans Schloesser, Volker Heinemann, Marion Subklewe, Stefan Boeck, Jens Werner & Michael von Bergwelt-Baildon. (2019) Advances in cancer immunotherapy 2019 – latest trends. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Zi-juan Qi, Dan Yu, Chun-hong Chen, Hong Jiang, Ran Li & Yong-ming Kang. (2019) The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis. The International Journal of Biological Markers 34:4, pages 373-380.
Crossref
Alain Wuethrich, Aswin Raj Rajkumar, Karthik Balaji Shanmugasundaram, Kamil K. Reza, Shuvashis Dey, Christopher B. Howard, Abu Ali Ibn Sina & Matt Trau. (2019) Single droplet detection of immune checkpoints on a multiplexed electrohydrodynamic biosensor. The Analyst 144:23, pages 6914-6921.
Crossref
Milena Music, Marco A.J. Iafolla, Annie He Ren, Antoninus Soosaipillai, Ioannis Prassas & Eleftherios P. Diamandis. (2019) Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value. Molecular Cancer Therapeutics 18:10, pages 1844-1851.
Crossref
Robert O. Dillman, Gabriel I. Nistor, Bryce T. McLelland, Candace Hsieh, Aleksandra J. Poole, Andrew N. Cornforth & Hans S. Keirstead. (2019) Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines. Oncotarget 10:51, pages 5359-5371.
Crossref
P. Hofman, S. Heeke, C. Alix-Panabières & K. Pantel. (2019) Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology 30:9, pages 1448-1459.
Crossref
Fabio Grizzi, Angelo Castello, Dorina Qehajaj, Luca Toschi, Sabrina Rossi, Daniela Pistillo, Valentina Paleari, Giulia Veronesi, Pierluigi Novellis, Simona Monterisi, Rossana Mineri, Daoud Rahal & Egesta Lopci. (2019) Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy 68:9, pages 1537-1545.
Crossref
Ji-Soo KwonJoung Ha ParkJi Yeun KimHye Hee ChaMin-Jae KimYong Pil ChongSang-Oh LeeSang-Ho ChoiYang Soo KimJun Hee WooYong Seo Koo, Sang-Beom Jeon, Sang-Ahm Lee & Sung-Han Kim. (2019) Diagnostic Usefulness of Cytokine and Chemokine Levels in the Cerebrospinal Fluid of Patients with Suspected Tuberculous Meningitis. The American Journal of Tropical Medicine and Hygiene 101:2, pages 343-349.
Crossref
Hyunkyung Park, Ju-Hee Bang, Ah-Rong Nam, Ji Eun Park, Mei Hua Jin, Yung-Jue Bang & Do-Youn Oh. (2019) Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Scientific Reports 9:1.
Crossref
Kostandinos Sideras, Robert A. de Man, Susan M. Harrington, Wojciech G. Polak, Guoying Zhou, Hannah M. Schutz, Alexander Pedroza-Gonzalez, Katharina Biermann, Shanta Mancham, Bettina E. Hansen, R. Bart Takkenberg, Anneke J. van Vuuren, Qiuwei Pan, Jan N. M. Ijzermans, Stefan Sleijfer, Dave Sprengers, Haidong Dong, Jaap Kwekkeboom & Marco J. Bruno. (2019) Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Scientific Reports 9:1.
Crossref
Yanyun Ruan, Wei Hu, Wanhong Li, Hongsheng Lu, Huamin Gu, Ying Zhang, Chumeng Zhu & Qi Chen. (2019) Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy. BioMed Research International 2019, pages 1-9.
Crossref
Francesca Romana Mariotti, Linda Quatrini, Enrico Munari, Paola Vacca & Lorenzo Moretta. (2019) Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. Frontiers in Immunology 10.
Crossref
Ugo Pastorino, Daniele Morelli, Giovanni Leuzzi, Luigi Rolli, Paola Suatoni, Francesca Taverna, Elena Bertocchi, Mattia Boeri, Gabriella Sozzi, Anna Cantarutti, Giovanni Corrao & Alessandro Gronchi. (2019) Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy. Annals of Surgical Oncology 26:3, pages 869-875.
Crossref
Kathleen M. Mahoney, Sachet A. Shukla, Nikolaos Patsoukis, Apoorvi Chaudhri, Edward P. Browne, Arnon Arazi, Thomas M. Eisenhaure, William F. PendergraftIIIIII, Ping Hua, Hung C. Pham, Xia Bu, Baogong Zhu, Nir Hacohen, Edward F. Fritsch, Vassiliki A. Boussiotis, Catherine J. Wu & Gordon J. Freeman. (2018) A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunology, Immunotherapy 68:3, pages 421-432.
Crossref
Boyang Chang, Tao Huang, Huajun Wei, Lujun Shen, Duo Zhu, Wenjun He, Qifeng Chen, Huihua Zhang, Yunjian Li, Ruopan Huang, Wang Li & Peihong Wu. (2018) The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy 68:3, pages 353-363.
Crossref
Tetsuro Tominaga, Takashi Akiyoshi, Noriko Yamamoto, Senzo Taguchi, Seiichi Mori, Toshiya Nagasaki, Yosuke Fukunaga & Masashi Ueno. (2019) Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PLOS ONE 14:2, pages e0212978.
Crossref
Shahrzad Jalali, Tammy Price-Troska, Cole Bothun, Jose Villasboas, Hyo-Jin Kim, Zhi-Zhang Yang, Anne J. Novak, Haidong Dong & Stephen M. Ansell. (2019) Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer Journal 9:3.
Crossref
Rituparna Chakrabarti, Bhavya Kapse & Gayatri Mukherjee. (2019) Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. CANCER REPORTS, pages e1160.
Crossref
K.Kamil Reza, Abu Ali Ibn Sina, Alain Wuethrich, Yadveer S. Grewal, Christopher B. Howard, Darren Korbie & Matt Trau. (2019) A SERS microfluidic platform for targeting multiple soluble immune checkpoints. Biosensors and Bioelectronics 126, pages 178-186.
Crossref
Jia Yang, Man Hu, Xinbin Bai, Xingchen Ding, Li Xie, Ji Ma, Bingjie Fan & Jinming Yu. (2019) Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC). Medicine 98:39, pages e17231.
Crossref
Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han & Kongming Wu. (2018) Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular Cancer 17:1.
Crossref
Lekh N. Dahal, Herbert Schwarz & Frank J. Ward. (2018) Hiding in Plain Sight: Soluble Immunomodulatory Receptors. Trends in Immunology 39:10, pages 771-774.
Crossref
Yusuke Okuma, Hiroshi Wakui, Hirofumi Utsumi, Yukiko Sagawa, Yukio Hosomi, Kazuyoshi Kuwano & Sadamu Homma. (2018) Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer. Clinical Lung Cancer 19:5, pages 410-417.e1.
Crossref
Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin Kim, Zhi-Zhang Yang, Anne J. Novak & Stephen M. Ansell. (2018) Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. Blood Advances 2:15, pages 1985-1997.
Crossref
Zehong Chen, Kang Hu, Lieting Feng, Ruxiong Su, Nan Lai, Zike Yang & Shijun Kang. (2018) Senescent cells re‐engineered to express soluble programmed death receptor‐1 for inhibiting programmed death receptor‐1/programmed death ligand‐1 as a vaccination approach against breast cancer. Cancer Science 109:6, pages 1753-1763.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.